A Phase 3, randomized, double-blind, placebo-controlled study evaluating Revumenib in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia with an NPM1 mutation (REVEAL-ND NPM1).
Principal Investigator
Dott.ssa Elena Crisà
Contact Information for Access
Phase
FASE III
Status
ATTIVO
Objective of the study
The objective of the study is to confirm that treatment with Revumebin plus intensive chemotherapy is clinically superior to chemotherapy alone.
Acute myeloid leukemia with NPM1 mutation
ClinicalTrials.gov ID NCT07211958
Sponsor: Syndax Pharmaceuticals
Pathologies
Onco-hematological (hematological cancers/malignancies)
Medication
Revumenib
Who is eligible to participate in the study?
Patients who are 18 years of age or older and meet the study’s eligibility criteria may participate in this study.
Patients with a new diagnosis of acute myeloid leukemia with an NPM1 mutation.
View the full study Back to search page